T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases.
Founded in 2022, the company is based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine.
Professor Allan Bradley has previously founded several companies including Kymab, a company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, which was acquired by Sanofi in 2021 for $1.45 billion.
T-Therapeutics has already raised investment from “a blue-chip syndicate of investors” to support its drug discovery efforts and prepare candidates for clinical development. It is currently building facilities, recruiting staff, and establishing its research operations.
Subscribe for alerts on new companies featured on Startups.Bio
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections. BioTryp's …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and autoimmune diseases. Bastion's GRIT™ (Genetically …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new class of genomic medicines that …
Founded in 2022, Couragene is a biotechnology company developing first-in-class in vivo genetic therapies using its proprietary delivery platforms. The company's technology holds potential for developing gene therapies for brain …